JP2018519810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519810A5 JP2018519810A5 JP2017562681A JP2017562681A JP2018519810A5 JP 2018519810 A5 JP2018519810 A5 JP 2018519810A5 JP 2017562681 A JP2017562681 A JP 2017562681A JP 2017562681 A JP2017562681 A JP 2017562681A JP 2018519810 A5 JP2018519810 A5 JP 2018519810A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 214
- 239000003814 drug Substances 0.000 claims 39
- 102000013498 tau Proteins Human genes 0.000 claims 23
- 108010026424 tau Proteins Proteins 0.000 claims 23
- 201000010099 disease Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 claims 8
- 102000057063 human MAPT Human genes 0.000 claims 8
- 208000000044 Amnesia Diseases 0.000 claims 7
- 208000026139 Memory disease Diseases 0.000 claims 7
- 230000001149 cognitive effect Effects 0.000 claims 7
- 230000006984 memory degeneration Effects 0.000 claims 7
- 208000023060 memory loss Diseases 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 208000034799 Tauopathies Diseases 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 241000282567 Macaca fascicularis Species 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 238000011374 additional therapy Methods 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 230000016784 immunoglobulin production Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 229940125759 BACE1 protease inhibitor Drugs 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010018341 Gliosis Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 101100029763 Rattus norvegicus Inpp5j gene Proteins 0.000 claims 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 230000006933 amyloid-beta aggregation Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000007387 gliosis Effects 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 210000002161 motor neuron Anatomy 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000002739 subcortical effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020186282A JP7403429B2 (ja) | 2015-06-05 | 2020-11-09 | 抗ｔａｕ抗体及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562171693P | 2015-06-05 | 2015-06-05 | |
| US62/171,693 | 2015-06-05 | ||
| PCT/US2016/035409 WO2016196726A1 (en) | 2015-06-05 | 2016-06-02 | Anti-tau antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020186282A Division JP7403429B2 (ja) | 2015-06-05 | 2020-11-09 | 抗ｔａｕ抗体及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519810A JP2018519810A (ja) | 2018-07-26 |
| JP2018519810A5 true JP2018519810A5 (https=) | 2019-11-28 |
| JP6793134B2 JP6793134B2 (ja) | 2020-12-02 |
Family
ID=56118083
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562681A Active JP6793134B2 (ja) | 2015-06-05 | 2016-06-02 | 抗ｔａｕ抗体及び使用方法 |
| JP2020186282A Active JP7403429B2 (ja) | 2015-06-05 | 2020-11-09 | 抗ｔａｕ抗体及び使用方法 |
| JP2023133420A Active JP7835706B2 (ja) | 2015-06-05 | 2023-08-18 | 抗ｔａｕ抗体及び使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020186282A Active JP7403429B2 (ja) | 2015-06-05 | 2020-11-09 | 抗ｔａｕ抗体及び使用方法 |
| JP2023133420A Active JP7835706B2 (ja) | 2015-06-05 | 2023-08-18 | 抗ｔａｕ抗体及び使用方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US10112990B2 (https=) |
| EP (2) | EP4465050A3 (https=) |
| JP (3) | JP6793134B2 (https=) |
| KR (1) | KR102768863B1 (https=) |
| CN (2) | CN114057872A (https=) |
| AR (1) | AR104875A1 (https=) |
| AU (2) | AU2016270858B2 (https=) |
| CA (2) | CA3258972A1 (https=) |
| CL (2) | CL2017003063A1 (https=) |
| CO (1) | CO2018000046A2 (https=) |
| CR (1) | CR20180013A (https=) |
| DK (1) | DK3303386T3 (https=) |
| ES (1) | ES2991587T3 (https=) |
| FI (1) | FI3303386T3 (https=) |
| IL (3) | IL300670B2 (https=) |
| MA (1) | MA44955A (https=) |
| MX (3) | MX392257B (https=) |
| NZ (2) | NZ775762A (https=) |
| PE (1) | PE20180317A1 (https=) |
| PH (2) | PH12021551770A1 (https=) |
| PL (1) | PL3303386T3 (https=) |
| PT (1) | PT3303386T (https=) |
| RU (1) | RU2732122C2 (https=) |
| SG (1) | SG10201911349YA (https=) |
| SI (1) | SI3303386T1 (https=) |
| TW (4) | TWI790642B (https=) |
| UA (1) | UA126272C2 (https=) |
| WO (1) | WO2016196726A1 (https=) |
| ZA (3) | ZA201707644B (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501531B2 (en) | 2013-03-13 | 2019-12-10 | Prothena Biosciences Limited | Tau immunotherapy |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| NZ775762A (en) | 2015-06-05 | 2025-02-28 | Genentech Inc | Anti-tau antibodies and methods of use |
| US10344081B2 (en) | 2015-07-06 | 2019-07-09 | Ucb Biopharma Sprl | Tau-binding antibodies |
| MY198194A (en) | 2016-05-02 | 2023-08-09 | Prothena Biosciences Ltd | Antibodies Recognizing Tau |
| PT3452507T (pt) | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Imunoterapia anti-tau |
| CA3032692A1 (en) * | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination antibody therapy for the treatment of neurodegenerative diseases |
| MX2019005116A (es) | 2016-11-01 | 2019-11-12 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). |
| MX2019006330A (es) * | 2016-12-07 | 2019-09-26 | Genentech Inc | Anticuerpos anti-tau y metodos de uso. |
| UA128383C2 (uk) | 2016-12-07 | 2024-07-03 | Дженентек, Інк. | Антитіло до тау-білка та спосіб його застосування |
| SG11201907422RA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| EP3601337A1 (en) * | 2017-03-28 | 2020-02-05 | Genentech, Inc. | Methods of treating neurodegenerative diseases |
| KR102784294B1 (ko) | 2017-05-02 | 2025-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| JP2020530554A (ja) * | 2017-07-20 | 2020-10-22 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用 |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| CN111787942B (zh) | 2017-10-25 | 2024-03-29 | 杨森制药公司 | 磷酸化Tau肽的组合物及其用途 |
| NL2020520B1 (en) * | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
| CA3093200A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Anti-phf-tau antibodies and uses thereof |
| US10591492B2 (en) * | 2018-03-05 | 2020-03-17 | Janssen Pharmaceutica Nv | Assays to detect neurodegeneration |
| WO2019173417A1 (en) * | 2018-03-08 | 2019-09-12 | Phanes Therapeutics, Inc. | Anti-tip-1 antibodies and uses thereof |
| CA3118692A1 (en) | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| CU24781B1 (es) * | 2018-11-08 | 2026-02-09 | Prothena Biosciences Ltd | Anticuerpos humanizados que reconocen tau |
| JP7547350B2 (ja) * | 2019-01-22 | 2024-09-09 | クレムソン・ユニバーシティ・リサーチ・ファウンデーション | 抗エラスチン抗体及び使用方法 |
| US12122843B2 (en) * | 2019-01-22 | 2024-10-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
| CN113286823B (zh) * | 2019-01-28 | 2024-05-07 | 上海拓界生物医药科技有限公司 | 抗cd79b抗体、其抗原结合片段及其医药用途 |
| WO2020163817A1 (en) * | 2019-02-08 | 2020-08-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
| MY206596A (en) | 2019-02-08 | 2024-12-25 | Janssen Pharmaceuticals Inc | Method of safe administration of phosphorylated tau peptide vaccine |
| JP7630834B2 (ja) | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| JOP20210284A1 (ar) * | 2019-04-24 | 2023-01-30 | Janssen Pharmaceuticals Inc | الإعطاء غير المتجانس للقاحات تاو |
| JP2022534406A (ja) * | 2019-05-27 | 2022-07-29 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | タウの立体配座特異的エピトープ、それらに対する抗体、およびそれらに関連する方法 |
| JP7227895B2 (ja) * | 2019-12-23 | 2023-02-22 | 株式会社堀場製作所 | 相互作用検出方法、相互作用検出装置及びバイオチップ再生キット |
| US20230391855A1 (en) * | 2020-10-21 | 2023-12-07 | La Jolla Institute For Immunology | Chimeric anti-sars-cov2 nucleoprotein antibodies |
| CN113005096B (zh) * | 2021-01-19 | 2022-10-14 | 华中科技大学 | 分泌抗丝氨酸磷酸化tau蛋白单克隆抗体的杂交瘤细胞株 |
| JP2024534151A (ja) * | 2021-08-27 | 2024-09-18 | ジェネンテック， インコーポレイテッド | タウ病態の治療方法 |
| WO2023039107A2 (en) * | 2021-09-09 | 2023-03-16 | Alzpath, Inc. | Phospho-tau antibodies and methods of use |
| US20250147051A1 (en) * | 2022-01-12 | 2025-05-08 | Gtinvent Limited | Method for detecting a tau protein in a saliva sample |
| WO2023245063A2 (en) * | 2022-06-14 | 2023-12-21 | The Johns Hopkins University | Identification of tdp-43 cryptic exon-encoded neoepitopes as functional fluid biomarkers for alzheimer's disease and related dementia |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| WO2025134068A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Antibody drug conjugates targeting proteinopathies, and uses thereof |
Family Cites Families (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU7121191A (en) * | 1990-02-26 | 1991-10-10 | Albert Einstein College Of Medicine Of Yeshiva University | Diagnostic assay for alzheimer's disease |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| EP1240319A1 (en) | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| AT500379B8 (de) * | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
| CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| AU2003292936A1 (en) | 2002-12-24 | 2004-07-22 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| ES2577292T3 (es) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| TW200812616A (en) | 2006-05-09 | 2008-03-16 | Genentech Inc | Binding polypeptides with optimized scaffolds |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| GB0624500D0 (en) | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| CN102459335B (zh) * | 2009-04-17 | 2015-11-25 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| SMT201700023T1 (it) * | 2010-08-02 | 2017-03-08 | Regeneron Pharma | Topi che producono proteine leganti vl |
| MY164376A (en) | 2010-10-07 | 2017-12-15 | Univ Leuven Kath | Phosphospecific antibodies recognizing tau |
| CA2813493C (en) | 2010-10-11 | 2019-07-09 | University Of Zurich | Human anti-tau antibodies |
| US9505826B2 (en) | 2010-12-22 | 2016-11-29 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
| US20120244174A1 (en) | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| ME03008B (me) | 2011-09-19 | 2018-10-20 | Axon Neuroscience Se | Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti |
| KR101981351B1 (ko) | 2011-10-07 | 2019-09-02 | 에이씨 이뮨 에스.에이. | 타우를 인식하는 포스포특이적 항체 |
| MX350311B (es) | 2011-12-20 | 2017-09-01 | Janssen Biotech Inc | Anticuerpos anti-phf-tau y sus usos. |
| RU2644242C2 (ru) * | 2012-04-05 | 2018-02-08 | Ац Иммуне С.А. | Гуманизированное тау-антитело |
| SG10201708959WA (en) | 2012-07-03 | 2017-11-29 | Univ Washington | Antibodies to tau |
| NZ630542A (en) * | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
| US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| EP2887955B1 (en) | 2012-08-21 | 2020-08-19 | Institute for Molecular Medicine, Inc. | Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein |
| EP2906596B1 (en) * | 2012-10-12 | 2023-12-27 | Arizona Board of Regents on behalf of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
| CA2896066C (en) | 2012-12-21 | 2022-07-12 | Biogen Ma Inc. | Human anti-tau antibodies |
| US9259211B2 (en) | 2012-12-24 | 2016-02-16 | Transmed7, Llc | Automated, selectable, soft tissue excision biopsy devices and methods |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| US10501531B2 (en) | 2013-03-13 | 2019-12-10 | Prothena Biosciences Limited | Tau immunotherapy |
| WO2014150877A2 (en) * | 2013-03-15 | 2014-09-25 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
| BR112015030356A2 (pt) * | 2013-06-10 | 2017-12-05 | Ipierian Inc | métodos de tratamento de uma taupatia |
| BR112016010454A2 (pt) | 2013-11-27 | 2017-12-05 | Ipierian Inc | métodos para tratar uma taupatia |
| AU2014368696A1 (en) | 2013-12-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Humanized anti-Tau(pS422) antibodies and methods of use |
| JP2017512751A (ja) | 2014-02-14 | 2017-05-25 | アイピエリアン，インコーポレイティド | タウペプチド、抗タウ抗体、およびそれらの使用方法 |
| TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| CA3001724A1 (en) | 2014-10-10 | 2016-04-14 | National Research Council Of Canada | Anti-tau antibody and uses thereof |
| US10323082B2 (en) | 2014-10-14 | 2019-06-18 | The Research Foundation For Mental Hygiene, Inc. | Treatment of tauopathies by passive immunization targeting the N-terminal projection domain of tau |
| CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| EP3261670A4 (en) | 2015-02-24 | 2018-08-01 | Rpeptide, LLC | Anti-tau antibodies |
| TWI669314B (zh) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | 針對ｔａｕ之抗體及其用途 |
| NZ775762A (en) | 2015-06-05 | 2025-02-28 | Genentech Inc | Anti-tau antibodies and methods of use |
| US20200030445A1 (en) | 2015-06-12 | 2020-01-30 | C2N Diagnostics, Llc | Stable formulations of humanized anti-tau antibody |
| WO2017005734A1 (en) | 2015-07-06 | 2017-01-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| US10344081B2 (en) | 2015-07-06 | 2019-07-09 | Ucb Biopharma Sprl | Tau-binding antibodies |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| US20190224339A1 (en) | 2016-04-29 | 2019-07-25 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| MY198194A (en) | 2016-05-02 | 2023-08-09 | Prothena Biosciences Ltd | Antibodies Recognizing Tau |
| PH12018502613B1 (en) | 2016-07-12 | 2023-02-01 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| UA128383C2 (uk) | 2016-12-07 | 2024-07-03 | Дженентек, Інк. | Антитіло до тау-білка та спосіб його застосування |
| MX2019006330A (es) | 2016-12-07 | 2019-09-26 | Genentech Inc | Anticuerpos anti-tau y metodos de uso. |
| EP3601337A1 (en) | 2017-03-28 | 2020-02-05 | Genentech, Inc. | Methods of treating neurodegenerative diseases |
-
2016
- 2016-06-02 NZ NZ775762A patent/NZ775762A/en unknown
- 2016-06-02 TW TW110121322A patent/TWI790642B/zh active
- 2016-06-02 PE PE2017002517A patent/PE20180317A1/es unknown
- 2016-06-02 NZ NZ737796A patent/NZ737796A/en unknown
- 2016-06-02 TW TW105117467A patent/TWI730963B/zh active
- 2016-06-02 PT PT167285592T patent/PT3303386T/pt unknown
- 2016-06-02 EP EP24192932.2A patent/EP4465050A3/en active Pending
- 2016-06-02 TW TW112144454A patent/TW202428606A/zh unknown
- 2016-06-02 US US15/171,143 patent/US10112990B2/en active Active
- 2016-06-02 SI SI201631870T patent/SI3303386T1/sl unknown
- 2016-06-02 SG SG10201911349YA patent/SG10201911349YA/en unknown
- 2016-06-02 CA CA3258972A patent/CA3258972A1/en active Pending
- 2016-06-02 CA CA2986942A patent/CA2986942C/en active Active
- 2016-06-02 TW TW111148795A patent/TWI827405B/zh active
- 2016-06-02 CR CR20180013A patent/CR20180013A/es unknown
- 2016-06-02 IL IL300670A patent/IL300670B2/en unknown
- 2016-06-02 KR KR1020177037588A patent/KR102768863B1/ko active Active
- 2016-06-02 UA UAA201713029A patent/UA126272C2/uk unknown
- 2016-06-02 WO PCT/US2016/035409 patent/WO2016196726A1/en not_active Ceased
- 2016-06-02 MA MA044955A patent/MA44955A/fr unknown
- 2016-06-02 CN CN202111063174.9A patent/CN114057872A/zh active Pending
- 2016-06-02 RU RU2017145540A patent/RU2732122C2/ru active
- 2016-06-02 AU AU2016270858A patent/AU2016270858B2/en active Active
- 2016-06-02 PL PL16728559.2T patent/PL3303386T3/pl unknown
- 2016-06-02 DK DK16728559.2T patent/DK3303386T3/da active
- 2016-06-02 FI FIEP16728559.2T patent/FI3303386T3/fi active
- 2016-06-02 IL IL314569A patent/IL314569A/en unknown
- 2016-06-02 ES ES16728559T patent/ES2991587T3/es active Active
- 2016-06-02 CN CN201680033214.6A patent/CN107849124B/zh active Active
- 2016-06-02 PH PH1/2021/551770A patent/PH12021551770A1/en unknown
- 2016-06-02 EP EP16728559.2A patent/EP3303386B1/en active Active
- 2016-06-02 AR ARP160101629A patent/AR104875A1/es unknown
- 2016-06-02 MX MX2017015464A patent/MX392257B/es unknown
- 2016-06-02 JP JP2017562681A patent/JP6793134B2/ja active Active
-
2017
- 2017-11-09 IL IL255578A patent/IL255578B2/en unknown
- 2017-11-10 ZA ZA2017/07644A patent/ZA201707644B/en unknown
- 2017-11-28 PH PH12017502165A patent/PH12017502165A1/en unknown
- 2017-11-30 MX MX2022003273A patent/MX2022003273A/es unknown
- 2017-11-30 MX MX2022003272A patent/MX2022003272A/es unknown
- 2017-12-01 CL CL2017003063A patent/CL2017003063A1/es unknown
-
2018
- 2018-01-02 CO CONC2018/0000046A patent/CO2018000046A2/es unknown
- 2018-09-24 US US16/140,189 patent/US10329344B2/en active Active
- 2018-09-24 US US16/140,182 patent/US10336819B2/en active Active
-
2019
- 2019-05-07 US US16/405,359 patent/US10633436B2/en active Active
- 2019-10-25 ZA ZA2019/07054A patent/ZA201907054B/en unknown
- 2019-10-29 CL CL2019003114A patent/CL2019003114A1/es unknown
-
2020
- 2020-11-09 JP JP2020186282A patent/JP7403429B2/ja active Active
- 2020-12-03 US US17/110,969 patent/US11555065B2/en active Active
-
2021
- 2021-10-18 ZA ZA2021/07931A patent/ZA202107931B/en unknown
-
2022
- 2022-07-25 AU AU2022209213A patent/AU2022209213A1/en not_active Abandoned
- 2022-12-13 US US18/065,472 patent/US12486319B2/en active Active
-
2023
- 2023-08-18 JP JP2023133420A patent/JP7835706B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519810A5 (https=) | ||
| IL266911B1 (en) | Anti-tau antibodies and uses thereof in treating tauopathy, retaining or increasing cognitive memory capacity or slowing memory loss | |
| FI3303386T3 (fi) | Tau-vasta-aineita ja käyttömenetelmiä | |
| JP2016503065A5 (https=) | ||
| JP2017536102A5 (https=) | ||
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| JP7357038B2 (ja) | 改善されたｔｎｆ結合因子 | |
| JP2019528083A5 (https=) | ||
| JP2019527543A5 (https=) | ||
| JP2016526878A5 (https=) | ||
| JP2022541539A5 (https=) | ||
| JP2015533795A5 (https=) | ||
| JP2021524267A5 (https=) | ||
| WO2013039954A1 (en) | Anti-gitr antibodies | |
| JP2020509756A5 (https=) | ||
| JP2016539176A5 (https=) | ||
| JP2019522961A5 (https=) | ||
| JP2023523401A5 (https=) | ||
| JP2017534646A5 (https=) | ||
| RU2013102225A (ru) | АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2013519364A5 (https=) | ||
| JP2013538553A5 (https=) | ||
| JP2019527194A5 (https=) | ||
| JP2015501814A5 (https=) | ||
| JP2018505651A5 (https=) |